Top in cardiology: Physical activity recommendation, icosapent ethyl treatment
Increasing physical activity levels may also help lower BP and blood cholesterol levels, according to a new American Heart Association recommendation.
A review of the society’s recommendation was the top story in cardiology last week.
Another top story indicated patients who were administered icosapent ethyl and had high or moderate eicosapentaenoic acid levels experienced better heart failure outcomes than those with low levels of that acid.
Read these and other top stories in cardiology below.
AHA statement recommends increasing physical activity to reduce BP, cholesterol
A new scientific statement from the American Heart Association published in Hypertension recommended increasing physical activity to aid in lowering mildly to moderately elevated BP and blood cholesterol in adults. Read more.
In high-risk patients taking icosapent ethyl, EPA levels linked to heart failure rates
In patients from the REDUCE-IT trial assigned icosapent ethyl, those who achieved high or moderate levels of eicosapentaenoic acid had better heart failure outcomes compared with those who achieved low levels, researchers reported. Read more.
AHA/ASA: ‘Benefits of vaccination far exceed the very small, rare risks’
The benefits of COVID-19 vaccination outweigh the risks despite the possibility of heart-related complications such as myocarditis, the American Heart Association and American Stroke Association announced in a statement. Read more.
Treatment initiative improves STEMI care in low-income, middle-income countries
The American College of Cardiology’s Global Heart Attack Treatment Initiative had considerable positive influence on care delivery for myocardial infarctions in low- and middle-income countries, according to a presentation at a recent meeting of the society. Read more.
Implantable ECG improves AF detection in patients with ischemic stroke
In patients with ischemic stroke and no prior evidence of atrial fibrillation, implantable ECG monitoring for 12 months detected atrial fibrillation more often than external monitoring for 30 days, according to the results of the PER DIEM trial. Read more.